Dompé evaluating intranasal spray for nonarteritic anterior ischemic optic neuropathy

The first patient has been enrolled in the phase 3 Galassia-NAION-301 study to evaluate an intranasal spray for the treatment of nonarteritic anterior ischemic optic neuropathy, according to a press release from Dompé. If approved, it would be the first FDA-approved treatment for nonarteritic anterior ischemic optic neuropathy (NAION), a spontaneous vision loss that can lead to permanent vision